These results collectively suggest that targeting the OX40L-OX40 axis could represent a novel, immunologically focused strategy to treat fibrotic progression in MASLD, addressing a current gap in therapeutic options that primarily target metabolic pathways. Here, TNFRSF4 is linked to metabolic dysfunction-associated steatotic liver disease.